Lead Sponsor

Biogen

Age

10 - 17 years

Sex

ALL

Healthy Volunteers

No

•Ability of parents, legal guardians, and/or subjects to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. Subjects will provide assent in addition to the parental or guardian consent, as appropriate, per local regulations.
•Subjects who completed, as per protocol, the previous BG00012 clinical study 109MS202 (NCT02410200) and remain on BG00012 treatment.

•Unwillingness or inability to comply with study requirements, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.
•Any significant changes in medical history occurring after enrollment in the parent Study 109MS202 (NCT02410200), including laboratory test abnormalities or current clinically significant conditions that in the opinion of the Investigator would have excluded the subject's participation from the parent study. The Investigator must re-review the subject's medical fitness for participation and consider any factors that would preclude treatment.
•Subjects from Study 109MS202 (NCT02410200) who could not tolerate study treatment.

Related studies

NCT05359653 · Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, and more

NCT06390930 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and more

NCT03401879 · Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis

NCT06389968 · Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis

NCT05834855 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and more

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)